Ziadeh Houda, Chaaya Monique, Rachidi Samar, Asmar Khalil El, Al-Hajje Amal, Hamieh Lamiaa, Nahra Vicky, Uthman Imad
Clinical and Epidemiological Research Laboratory, Faculty of Pharmacy, Doctoral School of Science and Technology, Lebanese University, Beirut, Lebanon.
Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
Mediterr J Rheumatol. 2022 Jun 30;33(2):218-223. doi: 10.31138/mjr.33.2.218. eCollection 2022 Jun.
The aim of the Lebanese hospital-based Rheumatoid Arthritis (RA) registry, initiated in 2011, is to evaluate the safety and efficacy of biologic agents among patients seeking care at the American University of Beirut Medical Center (AUBMC). We aimed to characterize the demographic and clinical profile of RA patients included in the Lebanese registry. We compared our results with those issued from Middle Eastern and non-Middle Eastern registries.
195 Patients enrolled in the RA registry from 2011 to 2018 were considered in this study. Patients enrolled in the registry were eligible to be treated with biologics, but 56 patients remained biologics naïve. Patients were reassessed every six months.
The highest proportion of patients were female (81%). The mean age was 55.53±15 years, and the disease duration was 11.38±7.7 years. RA was diagnosed at a mean age of 44.13±16 years. Almost one-third of RA patients were smokers (29.2%) and 15% consumed alcohol. Comorbidities included cardiac diseases (30.8%), hypertension (24.6%), hyperlipidemia (11.8%), diabetes mellitus (9.2%), and Hypothyroidism (6.2%). Three cases of cancer and seven cases of tuberculosis were reported. The mean of the Disease Activity Score (DAS28) was 3.75 ± 2.28 with no difference according to gender; the mean of the Health Assessment Questionnaire (HAQ) score showed a significant difference between females and males (1.02 ± 0.84 and 0.61 ± 0.7 respectively). Methotrexate was the most commonly used medication. There was non-significant difference in taking biologics according to gender.
Our findings are similar to other studies in terms of gender distribution. The higher mean age at diagnosis compared to other populations could indicate a delay in seeking appropriate care. The Lebanese RA registry provides valuable data on pharmacological interventions used and an opportunity to follow up to examine the effectiveness of different therapeutics and to monitor their side effects.
2011年启动的黎巴嫩医院类风湿关节炎(RA)登记系统,旨在评估在美国贝鲁特美国大学医疗中心(AUBMC)寻求治疗的患者中生物制剂的安全性和有效性。我们旨在描述纳入黎巴嫩登记系统的RA患者的人口统计学和临床特征。我们将我们的结果与中东和非中东登记系统发布的结果进行了比较。
本研究纳入了2011年至2018年登记在RA登记系统中的195例患者。登记系统中的患者有资格接受生物制剂治疗,但56例患者仍未使用过生物制剂。患者每六个月重新评估一次。
患者中女性比例最高(81%)。平均年龄为55.53±15岁,病程为11.38±7.7年。RA的诊断平均年龄为44.13±16岁。几乎三分之一的RA患者吸烟(29.2%),15%饮酒。合并症包括心脏病(30.8%)、高血压(24.6%)、高脂血症(11.8%)、糖尿病(9.2%)和甲状腺功能减退(6.2%)。报告了3例癌症和7例结核病病例。疾病活动评分(DAS28)的平均值为3.75±2.28,根据性别无差异;健康评估问卷(HAQ)评分的平均值在女性和男性之间存在显著差异(分别为1.02±0.84和0.61±0.7)。甲氨蝶呤是最常用的药物。根据性别使用生物制剂没有显著差异。
我们的发现在性别分布方面与其他研究相似。与其他人群相比,诊断时的平均年龄较高可能表明寻求适当治疗存在延迟。黎巴嫩RA登记系统提供了有关所用药理学干预的有价值数据,以及跟进检查不同治疗方法的有效性和监测其副作用的机会。